Lelievre P, Sancey L, Coll J, Deniaud A, Busser B
Cancers (Basel). 2020; 12(12).
PMID: 33255972
PMC: 7761132.
DOI: 10.3390/cancers12123524.
Mancinelli R, Cutone A, Rosa L, Lepanto M, Onori P, Pannarale L
Eur J Histochem. 2020; 64(4).
PMID: 33131269
PMC: 7586138.
DOI: 10.4081/ejh.2020.3156.
Jiang M, Qiao M, Zhao C, Deng J, Li X, Zhou C
Transl Lung Cancer Res. 2020; 9(4):1569-1584.
PMID: 32953528
PMC: 7481593.
DOI: 10.21037/tlcr-20-341.
Laparra J, Fotschki B, Haros C
Oncotarget. 2019; 10(7):760-772.
PMID: 30774778
PMC: 6366820.
DOI: 10.18632/oncotarget.26605.
Vela D
Front Oncol. 2018; 8:547.
PMID: 30538952
PMC: 6277552.
DOI: 10.3389/fonc.2018.00547.
p53 tumor suppressor and iron homeostasis.
Zhang J, Chen X
FEBS J. 2018; 286(4):620-629.
PMID: 30133149
PMC: 6379103.
DOI: 10.1111/febs.14638.
Role of hepcidin and iron metabolism in the onset of prostate cancer.
Zhao B, Li R, Cheng G, Li Z, Zhang Z, Li J
Oncol Lett. 2018; 15(6):9953-9958.
PMID: 29844842
PMC: 5958801.
DOI: 10.3892/ol.2018.8544.
Differential regulation of hepcidin in cancer and non-cancer tissues and its clinical implications.
Vela D, Vela-Gaxha Z
Exp Mol Med. 2018; 50(2):e436.
PMID: 29391539
PMC: 5903825.
DOI: 10.1038/emm.2017.273.
Gold-chrysophanol nanoparticles suppress human prostate cancer progression through inactivating AKT expression and inducing apoptosis and ROS generation in vitro and in vivo.
Lu L, Li K, Mao Y, Qu H, Yao B, Zhong W
Int J Oncol. 2017; 51(4):1089-1103.
PMID: 28849003
PMC: 5592865.
DOI: 10.3892/ijo.2017.4095.
Iron and cancer: recent insights.
Manz D, Blanchette N, Paul B, Torti F, Torti S
Ann N Y Acad Sci. 2016; 1368(1):149-61.
PMID: 26890363
PMC: 4870095.
DOI: 10.1111/nyas.13008.
Decreased expression of ferroportin in prostate cancer.
Xue D, Zhou C, Shi Y, Lu H, He X
Oncol Lett. 2015; 10(2):913-916.
PMID: 26622594
PMC: 4509077.
DOI: 10.3892/ol.2015.3363.
Iron, inflammation and invasion of cancer cells.
Fischer-Fodor E, Miklasova N, Berindan-Neagoe I, Saha B
Clujul Med. 2015; 88(3):272-7.
PMID: 26609256
PMC: 4632882.
DOI: 10.15386/cjmed-492.
Hepcidin - A novel biomarker with changing trends.
Kali A, Pravin Charles M, Seetharam R
Pharmacogn Rev. 2015; 9(17):35-40.
PMID: 26009691
PMC: 4441160.
DOI: 10.4103/0973-7847.156333.
Hepcidin regulation in prostate and its disruption in prostate cancer.
Tesfay L, Clausen K, Kim J, Hegde P, Wang X, Miller L
Cancer Res. 2015; 75(11):2254-63.
PMID: 25858146
PMC: 4454355.
DOI: 10.1158/0008-5472.CAN-14-2465.